RxDoctor Payments Data

Raymond Hsu, MD

Nephrology · San Francisco, CANPI 1124139167

Payments from drug & device makers

$304,400in general payments, 2019–2025

Across 106 payments — averaging $2871.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$109K
  • AstraZeneca$62K
  • Novartis$43K
  • Vertex$37K
  • Sanofi$27K
  • Travere Therapeutics, Inc.$19K
  • plus $7K from 10 others
$174in research payments, 2019–2025

Across 2 payments — averaging $86.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$174

What the payments were for

  • Consulting fees$55,97972%
  • Speaking & faculty fees$6,1808%
  • Travel & lodging$9,83513%
  • Food & beverage$5,4467%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304,400 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$129,579
Medicare patients
246
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FilspariSparsentan14$159,583
LupkynisVoclosporin11$135,861
FarxigaDapagliflozin Propanediol93$104,414
JardianceEmpagliflozin40$53,173
Sevelamer Carbonate41$32,932
Bumetanide28$2,196
Labetalol Hcl21$1,671
Telmisartan42$1,617
Nifedipine ErNifedipine15$922
Losartan Potassium43$574
Hydralazine Hcl12$548
Furosemide62$452
Amlodipine Besylate61$402
Carvedilol31$366
Metoprolol Succinate22$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Travere Therapeutics, Inc.Filspari$18,856$159,58314 claims
Aurinia Pharma U.S., Inc.Lupkynis$455$135,86111 claims
AstraZenecaFarxiga$62,239$104,41493 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →